BP180 and BP230 (Bullous Pemphigoid), IgG Antibodies
Use
This test is a preferred screening method for diagnosing patients suspected to have bullous pemphigoid and related conditions. It detects circulating IgG antibodies that target specific proteins at the dermal-epidermal junction, including BP180 and BP230. These proteins play essential roles in maintaining skin structure, and their targeting by autoantibodies results in blister formation typical of pemphigoid diseases. Monitoring antibody levels can also help evaluate the effectiveness of therapeutic interventions aimed at managing these conditions.
Special Instructions
Not provided.
Limitations
The test may yield false-negative results if antibody levels are below the detection threshold or if there is insufficient sample volume. Cross-reactions with other proteins that are not related to bullous pemphigoid might occur, affecting test specificity. Incorrect sample handling, such as bacterial contamination or hemolysis, can lead to sample rejection and unsuccessful testing.
Methodology
Immunoassay (EIA)
Biomarkers
BP180
ProteinBP230
Protein
LOINC Codes
- 92671-7 - BMZ BP180 + BP230 IgG Pnl SerPl
- 53842-1 - BMZ BP180 IgG SerPl-aCnc
- 53843-9 - BMZ BP230 IgG SerPl-aCnc
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
Gel-barrier tube, red-top tube or serum transfer tube
Collection Instructions
Serum samples may be stored for up to eight hours at room temperature before freezing at -20°C. Samples should not be repeatedly frozen and thawed.
Storage Instructions
Frozen at -20°C
Causes for Rejection
Bacterial contamination, hemolysis, lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unstable |
| Refrigerated | Unstable |
| Frozen | 14 days |
Other tests from different labs that may be relevant